Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
10592studies shown
Showing 9,241-9,252 of 10,592
Drug study icon
CompletedNCT01716975

EVP-6124 (Alpha-7 nAChR) for schizophrenia

This study is completed in the United States, in Australia, in the United Kingdom, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.

In United States
SchizophreniaDrugA study involving a medication or substance.From 18 Years to 50 Years
Countries
United States, Australia, United Kingdom, ...
Sponsor
FORUM Pharmaceuticals Inc
Condition
Schizophrenia
Other study type icon
CompletedNCT00342953

Health Effects of Cosmetic Breast Augmentation

This summary needs review. Please check the official study record and contact the research team for details.

In United States
SuicidalityOtherFrom 21 Years to 69 Years
Countries
United States
Sponsor
National Cancer Institute (NCI)
Condition
Suicidality
Drug study icon
CompletedNCT01979133

Icariin for Bipolarity and Co-Occurring Substance Use Disorders

This study exists to explore whether the medication Icariin could improve care and understanding. Researchers are trying to understand whether the medication Icariin can improve attention, thinking, or day-to-day functioning.

In United States
Bipolarity, AddictionDrugFrom 18 Years to 70 Years
Countries
United States
Sponsor
University of Texas Southwestern Medical Center
Condition
Bipolarity, Addiction
Drug study icon
TerminatedNCT06374290

Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

This study exists to see whether the medication Injectable is workable and worth testing more broadly. Researchers are trying to understand how people respond to the medication Injectable in practice and what may need to be adjusted.

In United States
SchizophreniaDrugOver 18 Years
Countries
United States
Sponsor
The University of Texas Health Science Center, Houston
Condition
Schizophrenia
Drug study icon
CompletedNCT00107939

Licarbazepine in the Treatment of manic episodes of Bipolarity

This study exists to see whether the medication Licarbazepine can play a useful role in care. Researchers are trying to understand how people respond to the medication Licarbazepine in practice and what may need to be adjusted.

In United States
BipolarityDrugFrom 18 Years to 70 Years
Countries
United States
Sponsor
Novartis Pharmaceuticals
Condition
Bipolarity
Drug study icon
CompletedNCT01731119

Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

This study exists to see whether the medication Lurasidone is workable and worth testing more broadly. Researchers are trying to understand whether the medication Lurasidone can give earlier or clearer feedback during care.

In United States
Schizophrenia, Bipolarity, ...DrugFrom 6 Years to 19 Years
Countries
United States
Sponsor
University of North Carolina, Chapel Hill
Condition
Schizophrenia, Bipolarity, ...
Drug study icon
TerminatedNCT00575328

Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolarity in Females

This study exists to compare options and see whether the medication Maca offers something meaningfully different. Researchers are trying to understand how people respond to the medication Maca in practice and what may need to be adjusted.

In United States
BipolarityDrugFrom 18 Years to 80 Years
Countries
United States
Sponsor
Massachusetts General Hospital
Condition
Bipolarity
Drug study icon
CompletedNCT00833443

Medical Treatment for Methamphetamine Addiction

This summary needs review. Please check the official study record and contact the research team for details.

In United States
AddictionDrugOver 18 Years
Countries
United States
Sponsor
University of California, Los Angeles
Condition
Addiction
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.